Jazz Pharmaceuticals has reached an agreement to buy Nasdaq-listed Chimerix for around $935 million, adding a brain cancer drug that is heading for an FDA verdict in the summer. The Irish and US ...
The Elder Scrolls's lore is so complicated that picking out the most powerful characters can be difficult. However, we are ...
Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...
"I sit here just knowing that my babies are a part of me on a cellular level and that healed something in me when I heard ...
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an update.
Hosted on MSN
Chimeric's AML trial hits 60% response as ASX dips
Chimeric Therapeutics reported a 60% complete response rate in its Phase 1b AML trial, far exceeding the 20–30% standard of care. The announcement came as the ASX opened lower amid geopolitical ...
Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors ...
Five-year collaboration supports consistent clinical supply for Phase 1A/1B GI cancer study PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results